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In the publication of this article \[[@CR1]\], there are two corrections: 1. The corresponding author Yuanzhong Chen's email should be changed to chenyz\@mail.fjmu.edu.cn; 2. Several figures Fig. [5](#Fig1){ref-type="fig"}, Fig. [8](#Fig2){ref-type="fig"}, and Additional files 5, 6, 9 and 10 need to be corrected, because the formats are wrong, and the revised figures are shown below. Fig. 5Homoharringtonine (HHT) combined with arsenic trioxide (ATO) decrease the proportion of primary leukemia stem cells (LSCs) in serum free medium with cytokine cocktail (Flt3L, SCF, IL-3 and IL-6). Quantification of frequencies of CD34^+^cells (**a**), CD34^+^/CD38^−^ cells (**b**) and CD34^+^/CD38^−^/CD96^+^ cells (**c**). (**d**) Display of flow cytometric analysis on bone marrow sample of patient no. 2 after treatment with HHT and ATO alone or combined. (**e**) Represents the proportion of normal primary CD34+/CD38- (*n* = 3) Fig. 8Homoharringtonine (HHT) combined with arsenic trioxide (ATO) remarkably obliterated the histological infiltration of leukemia stem cells (LSCs). (**a**) H&E-stained sections of representative 4% paraformaldehyde-fixed spleens and bone marrow from NRG mice. (**b**) hCD45 and hCD34 levels were detected in the different groups by confocal laser-scanning microscopy in representative 4% paraformaldehyde-fixed spleens and bone marrow samples from NRG mice. Scale bars: 50 μm Table S1Patients characteristicNO.GenderAgeWBC(\*10^9^/L)Hb (g/L)PLT (\*10^9^/L)FAB typeBM Blasts(%)Immune markersKaryotype1female231.85124168M063.2CD7, CD117, HLA-DR46 XX2male2912.721387M560.3CD7,HLA-DR, CD3346 XY3male321.14464M2a80MPO,CD99,CD11746 XY t(8;21)4female365.575083M5b78CD117, CD33,MPO46 XX5female4320.574510M172CD117, CD33, MPO46 XX6female2519.63423M069.3CD7, CD117, MPO46 XX7male2927233M559.6CD33, HLA-DR CD1546 XYNO.1-4 were used to FCM (Flow Cytometry) analysis; NO.5-7 were used to synergistic effect. NO.7 were also used for WB Table S2Primer Sequences for PCRGenePrimer Sequencesβ-actinForward 5'-GCCAACCGCGAGAAGATGA-3'Reverse 5'-CATCAGGATGCCAGTGGT-3'CD34Forward 5'- ACTCGGTGCGTCTCTCTAGG -3'Reverse 5'- CCGTGAGACTCTGCTCTGC-3'CD38Forward 5'- TTG GGA ACTCAG ACC GTA CCT TG-3'Reverse 5'- CCA CAC CAT GTGAGG TCA TC-3'CD96Forward 5'- ACCACAGTCAAGGTTTTTG-3'Reverse 5'- CCAGGCTGGAGAAGGTTGG-3'

The original article has been corrected.
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Additional file 5: Figure S5. Homoharringtonine (HHT) combined with arsenic trioxide (ATO) decrease the proportion of primary leukemia stem cells (LSCs) in serum free medium with cytokine cocktail (Flt3L, SCF, IL-3 and IL-6). Quantification of frequencies of CD34+cells (A), CD34+/CD38−cells (B) and CD34+/CD38−/CD96+ cells (C) from patient 4. (D) Display of flow cytometric analysis on bone marrow sample after treatment with HHT and ATO alone or combined.

Additional file 6: Figure S6. Homoharringtonine (HHT) combined with arsenic trioxide (ATO) more effectively damaged the primary CD34+CD38− cells than CD34+/CD38+ cells in serum-free medium with a cytokines cocktail (Flt3L, SCF, IL-3 and IL-6). (A--C) Quantification of frequencies of Annexin V-positive cells in CD34+CD38− and CD34+CD38+ cells from patient 1 (A), patient 2 (B), patient 3 (C), patient 4 (D). (E) Representative flow cytometric analysis of patient 2 for apoptosis using Annexin V and stem cells markers (CD34, CD38).

Additional file 9: Table S1. Patients characteristic.

Additional file 10: Table S2. Primer Sequences for PCR.
